Amicus Therapeutics (FOLD) Coverage Initiated by Analysts at Citigroup

Citigroup assumed coverage on shares of Amicus Therapeutics (NASDAQ:FOLD) in a report released on Monday, Marketbeat.com reports. The firm issued a neutral rating and a $12.00 price objective on the biopharmaceutical company’s stock.

Several other equities analysts also recently weighed in on FOLD. Zacks Investment Research upgraded Amicus Therapeutics from a hold rating to a buy rating and set a $18.00 price target for the company in a report on Tuesday, July 10th. ValuEngine downgraded Amicus Therapeutics from a strong-buy rating to a buy rating in a report on Thursday, July 19th. BidaskClub downgraded Amicus Therapeutics from a hold rating to a sell rating in a report on Saturday, July 28th. Chardan Capital downgraded Amicus Therapeutics from a buy rating to a neutral rating and reduced their price target for the company from $18.00 to $15.00 in a report on Friday, August 17th. Finally, Cowen restated a buy rating and set a $31.00 price target on shares of Amicus Therapeutics in a report on Friday, October 12th. One research analyst has rated the stock with a sell rating, two have issued a hold rating, four have issued a buy rating and one has issued a strong buy rating to the stock. Amicus Therapeutics presently has an average rating of Buy and an average price target of $19.50.

FOLD traded down $0.03 during trading on Monday, reaching $11.11. The stock had a trading volume of 610,028 shares, compared to its average volume of 3,145,420. Amicus Therapeutics has a one year low of $10.33 and a one year high of $17.62. The company has a current ratio of 10.88, a quick ratio of 10.73 and a debt-to-equity ratio of 0.30. The company has a market cap of $2.19 billion, a price-to-earnings ratio of -3.80 and a beta of 1.33.

Amicus Therapeutics (NASDAQ:FOLD) last issued its quarterly earnings results on Tuesday, August 7th. The biopharmaceutical company reported ($0.33) earnings per share for the quarter, meeting the consensus estimate of ($0.33). Amicus Therapeutics had a negative return on equity of 53.45% and a negative net margin of 460.04%. The firm had revenue of $21.31 million during the quarter, compared to the consensus estimate of $18.92 million. On average, analysts predict that Amicus Therapeutics will post -1.19 EPS for the current year.

In other Amicus Therapeutics news, major shareholder Perceptive Advisors Llc acquired 20,000 shares of the company’s stock in a transaction that occurred on Monday, September 24th. The shares were bought at an average cost of $12.45 per share, with a total value of $249,000.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, major shareholder Life Sciences Maste Perceptive acquired 500,000 shares of the company’s stock in a transaction that occurred on Wednesday, September 12th. The shares were acquired at an average cost of $12.00 per share, for a total transaction of $6,000,000.00. The disclosure for this purchase can be found here. Insiders have purchased 620,000 shares of company stock worth $7,505,000 over the last ninety days. 2.90% of the stock is currently owned by insiders.

Several institutional investors have recently added to or reduced their stakes in the stock. Xact Kapitalforvaltning AB boosted its position in shares of Amicus Therapeutics by 14.0% during the second quarter. Xact Kapitalforvaltning AB now owns 29,241 shares of the biopharmaceutical company’s stock valued at $457,000 after buying an additional 3,600 shares during the last quarter. Strs Ohio boosted its position in Amicus Therapeutics by 32.2% in the second quarter. Strs Ohio now owns 16,000 shares of the biopharmaceutical company’s stock worth $249,000 after purchasing an additional 3,900 shares during the last quarter. Amalgamated Bank boosted its position in Amicus Therapeutics by 16.1% in the second quarter. Amalgamated Bank now owns 28,896 shares of the biopharmaceutical company’s stock worth $451,000 after purchasing an additional 4,011 shares during the last quarter. Berson & Corrado Investment Advisors LLC boosted its position in Amicus Therapeutics by 14.0% in the second quarter. Berson & Corrado Investment Advisors LLC now owns 36,870 shares of the biopharmaceutical company’s stock worth $575,000 after purchasing an additional 4,514 shares during the last quarter. Finally, Great West Life Assurance Co. Can boosted its position in Amicus Therapeutics by 33.5% in the second quarter. Great West Life Assurance Co. Can now owns 20,494 shares of the biopharmaceutical company’s stock worth $320,000 after purchasing an additional 5,148 shares during the last quarter.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. The company offers migalastat HCl, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting a Phase 1/2 clinical study of ATB200-02 to investigate in patients with pompe disease.

Read More: Outstanding Shares, Buying and Selling Stocks

Analyst Recommendations for Amicus Therapeutics (NASDAQ:FOLD)

Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply